glutathione for als Impaired antioxidant KEAP1-NRF2 system in amyotrophic lateral sclerosis: NRF2 activation as a potential therapeutic strategy | Molecular Neurodegeneration Effect of amyotrophic lateral sclerosis
Description
Stabilized 15-residue research peptide compound in arginate salt form
Psychiatry 23 , 13851392 (2018)
Based on this understanding, IgG1 monoclonal antibodies that directly target various forms A plaques have been developed, resulting in drugs such as Aducanumab (marketed as Aduhelm) that has been approved for use by the FDA (Dhillon, 2021)
B 12 deficiency can cause preventable permanent injury and should be considered with new onset neurological conditions and symptoms suggestive of B 12 deficiency (See Low B 12 symptoms section below)
